Jhaqueline Valle

Jhaqueline Valle

Auto-generated profile, based on publicly available information

Jhaqueline Valle

Tracking California, Public Health Institute, Oakland, CA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2024 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
JVJhaqueline Valle
Jhaqueline Valle
JLJeffrey D Lebensburger
Jeffrey D Lebensburger
PGPranav Garimella
Pranav Garimella
SGSrila Gopal
Srila Gopal
Background: Chronic kidney disease (CKD) is a significant complication in patients with sickle cell disease (SCD), leading to increased mortality. Objective: This study aims to investigate the burden of CKD in Medicaid-enrolled adults with SCD in California, examine differences in disease burden between male and female individuals, and assess mortality rates and access to specialized care. Methods: This retrospective cohort study used the California Sickle Cell Data Collection program to identify and monitor individuals with SCD. Medicaid claims, vital records, emergency department, and hospitalization data from 2011 to 2020 were analyzed. CKD prevalence was assessed based on ICD (International Classification of Diseases) codes, and mortality rates were calculated. Access to specialized care was examined through outpatient encounter rates with hematologists and nephrologists. Results: Among the 2345 adults with SCD, 24.4% (n=572) met the case definition for CKD. The SCD-CKD group was older at the beginning of this study (average age 44, SD 14 vs 34, SD 12.6 years) than the group without CKD. CKD prevalence increased with age, revealing significant disparities by sex. While the youngest (18-29 years) and oldest (>65 years) groups showed similar CKD prevalences between sexes (female: 12/111, 10.8% and male: 12/101, 11.9%; female: 74/147, 50.3% and male: 34/66, 51.5%, respectively), male individuals in the aged 30-59 years bracket exhibited significantly higher rates than female individuals (30-39 years: 49/294, 16.7%, P=.01; 40-49 years: 52/182, 28.6%, P=.02; and 50-59 years: 76/157,48.4%, P<.001). During this study, of the 2345 adults, 435 (18.5%) deaths occurred, predominantly within the SCD-CKD cohort (226/435, 39.5%). The median age at death was 53 (IQR 61-44) years for the SCD-CKD group compared to 43 (IQR 33-56) years for the SCD group, with male individuals in the SCD-CKD group showing significantly higher mortality rates (111/242, 45.9%; P=.009) than female individuals (115/330, 34.9%). Access to specialist care was notably limited: approximately half (281/572, 49.1%) of the SCD-CKD cohort had no hematologist visits, and 61.9% (354/572) did not see a nephrologist during this study’s period. Conclusions: This study provides robust estimates of CKD prevalence and mortality among Medicaid-enrolled adults with SCD in California. The findings highlight the need for improved access to specialized care for this population and increased awareness of the high mortality risk and progression associated with CKD.

27 October 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JVJhaqueline Valle
Jhaqueline Valle
JBJudith Baker
Judith Baker
DMDaniel Madrigal
Daniel Madrigal
JFJuana Ferrerosa
Juana Ferrerosa
SPSusan Paulukonis
Susan Paulukonis
Introduction: After African Americans, Latinx are the second largest population affected by Sickle Cell Disease (SCD) in the U.S. However, research has largely ignored how this devastating rare blood disorder specifically affects Latinx nationwide.Methods: This study compared demographics, genotypes, primary insurance, and health care utilization among Latinx and non-Latinx Californians living with SCD, using data from the California SCD Data Collection Program (2016–2018) and newborn screening cases 2000–2017.Results: Stemming from 6,837 SCD patients, 501(7%) were Latinx. Latinx with SCD (Lx-SCD) were statistically significantly younger than non-Latinx (NLx-SCD) counterparts. Within both groups, females predominated, with 70% being insured by Medicaid. Mean Emergency Department encounters were statistically significantly lower among Lx-SCD adults.Discussion: Lx-SCD differ in age, genotype, and Emergency Department utilization, when compared to NLx-SCD counterparts in California. Latinx are now the largest racial and/or ethnic group in the US, and their presence in SCD population is expected to grow. Therefore, their specific demographic, genotypic, and health care utilization characteristics merit attention to inform policies and programs that will improve their health.

17 January 2025 in Journal of Sickle Cell Disease
Verified
Journal Article
Open access
ASAli San
Ali San
CCCatie Clyde
Catie Clyde
DYDennis Yap
Dennis Yap
SPSusan Paulukonis
Susan Paulukonis
JVJhaqueline Valle
Jhaqueline Valle
KQKeith Quirolo
Keith Quirolo
Sickle cell disease (SCD) represents a major health challenge, affecting more than 100 000 people in the United States. Patients develop severe systemic manifestations from vaso-occlusive episodes, leading to severe pain crises and reduction of life expectancy. Despite its prevalence, individuals with SCD face not only dire health complications but also encounter systemic barriers to healthcare access and treatment. This exploratory study aims to provide preliminary insights into these challenges by examining the healthcare landscape for SCD patients in California, focusing on the accessibility and distribution of hematology clinics’ resources. Through a collaborative multi-site survey conducted, the study gathered insights from 44 hematology clinics. We explored adherence to treatment guidelines, the availability of specialty referrals, support services, clinic operational hours, and the impact of patient population size on service provision. The findings reveal potential gaps in guideline adherence, specialty referrals, and clinic operation times in clinics that serve ≤40 SCD patients. There is a scarcity of support roles such as community health workers and healthcare navigators across all clinics regardless of SCD population size. These preliminary insights underscore the need for further research and strategic interventions to improve access to comprehensive care and support for SCD patients. By highlighting potential disparities faced by SCD patients in California, this study provides a foundation for public health institutes to assess healthcare resources and develop effective solutions to enhance patient outcomes and quality of life.

28 January 2026 in Public Health Reports®
Verified
Journal Article
Open access
ASAngela B. Snyder
Angela B. Snyder
MZMei Zhou
Mei Zhou
JVJhaqueline Valle
Jhaqueline Valle
JBJeanne Boudreaux
Jeanne Boudreaux
RYRobert Yamashita
Robert Yamashita
ALAshutosh Lal
Ashutosh Lal
Objective: An accurate estimate of the prevalence, demographic characteristics, and geographic distribution of thalassemia in the United States is needed to plan for the health care needs of people with this disease. We developed and evaluated the predictive value of administrative case definitions for correctly identifying people living with thalassemia. Methods: We conducted a retrospective study of the diagnostic accuracy of 3 claims-based case definitions to identify people with thalassemia in Medicaid administrative data from 2012 through 2019. Case definition 1 was ≥5 encounters with a code for thalassemia; case definition 2 was ≥1 encounter with a code for thalassemia and ≥6 encounters with a transfusion code; and case definition 3 was ≥2 encounters with a code for thalassemia and a transfusion code occurring on the same encounters. We validated our findings by using confirmatory laboratory assessment and expert review by clinicians at thalassemia treatment centers in Georgia (Children’s Healthcare of Atlanta) and California (University of California San Francisco) as the gold standard. Results: Of the 327 people identified, thalassemia was confirmed in 173 (52.9%), excluded in 68 (20.7%), and found indeterminate in 86 (26.2%) people. Case definition 1 had the lowest positive predictive value (PPV) (range, 55%-77%). For case definition 2, the PPV range was 80% to 86%. For case definition 3, the PPV range was the highest (82%-96%) but also captured more indeterminate cases. Conclusions: Accurately identifying patients with thalassemia using a case definition based on administrative claims data is feasible. Extending our method to other health care databases beyond Medicaid may allow for an estimate of the national prevalence of transfusion-dependent thalassemia. However, cases of nontransfusion-dependent thalassemia were difficult to define with sufficient precision.

11 February 2024 in JMIR Preprints
Verified
Preprint
Open access
JVJhaqueline Valle
Jhaqueline Valle
JLJeffrey D Lebensburger
Jeffrey D Lebensburger
PGPranav Garimella
Pranav Garimella
SGSrila Gopal
Srila Gopal
BACKGROUND Chronic kidney disease (CKD) is a significant complication in patients with sickle cell disease (SCD), leading to increased mortality. OBJECTIVE This study aims to investigate the burden of CKD in Medicaid-enrolled adults with SCD in California, examine differences in disease burden between male and female individuals, and assess mortality rates and access to specialized care. METHODS This retrospective cohort study used the California Sickle Cell Data Collection program to identify and monitor individuals with SCD. Medicaid claims, vital records, emergency department, and hospitalization data from 2011 to 2020 were analyzed. CKD prevalence was assessed based on ICD (International Classification of Diseases) codes, and mortality rates were calculated. Access to specialized care was examined through outpatient encounter rates with hematologists and nephrologists. RESULTS Among the 2345 adults with SCD, 24.4% (n=572) met the case definition for CKD. The SCD-CKD group was older at the beginning of this study (average age 44, SD 14 vs 34, SD 12.6 years) than the group without CKD. CKD prevalence increased with age, revealing significant disparities by sex. While the youngest (18-29 years) and oldest (>65 years) groups showed similar CKD prevalences between sexes (female: 12/111, 10.8% and male: 12/101, 11.9%; female: 74/147, 50.3% and male: 34/66, 51.5%, respectively), male individuals in the aged 30-59 years bracket exhibited significantly higher rates than female individuals (30-39 years: 49/294, 16.7%, P=.01; 40-49 years: 52/182, 28.6%, P=.02; and 50-59 years: 76/157,48.4%, P<.001). During this study, of the 2345 adults, 435 (18.5%) deaths occurred, predominantly within the SCD-CKD cohort (226/435, 39.5%). The median age at death was 53 (IQR 61-44) years for the SCD-CKD group compared to 43 (IQR 33-56) years for the SCD group, with male individuals in the SCD-CKD group showing significantly higher mortality rates (111/242, 45.9%; P=.009) than female individuals (115/330, 34.9%). Access to specialist care was notably limited: approximately half (281/572, 49.1%) of the SCD-CKD cohort had no hematologist visits, and 61.9% (354/572) did not see a nephrologist during this study’s period. CONCLUSIONS This study provides robust estimates of CKD prevalence and mortality among Medicaid-enrolled adults with SCD in California. The findings highlight the need for improved access to specialized care for this population and increased awareness of the high mortality risk and progression associated with CKD.